Treatment Registry
TR-0951 ActiveRecorded October 2026

Compounded tirzepatide

Sold by Candor Rx · every compounded tirzepatide record

The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.

Price

No comparable monthly price verified at this reading. See dated notes for any advertised starting figures.

Visit Candor Rx

We earn nothing from this link. It opens Candor Rx's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • October 2026 — Entry added to the register

Sourcing and terms

PharmacyManifest Pharmacy is named in the network; assignment depends on therapy and medication.
StatesNot disclosed
PrescriberBoth
CancellationCancel through the account before shipment. After payment and carrier handoff, prescription sales are final; damaged or lost orders require contacting support.
MembershipNot disclosed
Consult feeNot disclosed

Recorded from candorrx.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. October 2026 — The molecule-specific card starts at $149 monthly, but the shared headline advertises $95. Confirm the selected offer and invoice; the actual device is not established. https://candorrx.com/
  2. 2. October 2026 — Consultations are included in most cases, not universally. Review may use intake answers or a live interaction depending on state. https://candorrx.com/faq/
  3. 3. October 2026 — The FAQ lists 49 service states, excluding Alaska, without a medication-specific roster. Billing occurs at shipment. https://candorrx.com/faq/
  4. 4. October 2026 — Prescription returns differ from nonprescription returns. https://candorrx.com/return-refund-policy/

1 further note concerns other Candor Rx programs and sit on the provider record.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0951
Medication category
compounded tirzepatide
Readings
1

Related records

Cite this entry

Treatment Registry. (2026). Candor Rx — compounded tirzepatide (TR-0951). Last verified October 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0951

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.